NPM1 and acute myeloid leukemia: Similarly, the 2024 National Comprehensive Cancer Network (NCCN) AML guidelines advocate for the systematic use of sensitive techniques such as quantitative real-time polymerase chain reaction (RT-PCR) for NPM1 to evaluate MRD and support a personalized, risk-adapted approach based on both molecular and clinical profiles [20].